Vertex Pharmaceuticals
Jun 18, 2015
PDF

Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Sangeeta N. Bhatia, M.D., Ph.D., joined its board of directors as an independent director. Dr. Bhatia was elected to serve a three-year term ending in 2018.

"Dr. Bhatia is a leading physician scientist and medical researcher who brings a wealth of expertise to our board," said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. "Her extensive experience in the field of biomedical engineering and in-depth understanding on the use of advanced technologies in medical research will provide valuable insights to our board and our company as we advance key research and development programs."

Dr. Bhatia is a physician and engineer and has been a professor at the Massachusetts Institute of Technology (MIT) since 2005. She currently serves as the John J. and Dorothy Wilson Professor of Health Sciences at the MIT Institute for Medical Engineering and Science and Electrical Engineering and Computer Science (EECS). She also currently serves as a Biomedical Engineer in the Department of Medicine for Brigham and Women's Hospital, an investigator for the Howard Hughes Medical Institute, a member of the Koch Institute for Integrative Cancer Research at MIT and a member of the Broad Institute. She recently received the Heinz Award for Technology, the Economy, and Employment from the Heinz Family Foundation and the Lemelson-MIT Prize for her dedication to STEM education and to improving human health through technological innovations. From 1998 to 2005, Dr. Bhatia was a professor of bioengineering and medicine at the University of California at San Diego. Dr. Bhatia holds a B.S. in Biomedical Engineering from Brown University, an M.S. in Mechanical Engineering and Ph.D. in Biomedical Engineering from MIT, and an M.D. from Harvard Medical School.

"I believe Vertex has a unique opportunity to integrate new medical technologies into its research and development programs in cystic fibrosis and other diseases in the years ahead," said Dr. Bhatia. "I look forward to providing my insights as both a physician and scientist to Vertex's board at this exciting time."

About Vertex

Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to our clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases.

Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For five years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences. For additional information and the latest updates from the company, please visit www.vrtx.com.

(VRTX-GEN)

Vertex Pharmaceuticals Incorporated
Investors:
Michael Partridge, 617-341-6108
or
Media:
Zach Barber, 617-341-6470
MediaInfo@vrtx.com

Source: Vertex Pharmaceuticals Incorporated

News Provided by Acquire Media